9.01

3.22% -0.30

Kura Oncology Inc (KURA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$9.31

Aprire:

$9.465

Volume 24 ore:

1.17M

Relative Volume:

0.70

Capitalizzazione di mercato:

$799.86M

Reddito:

$71.64M

Utile/perdita netta:

$-294.57M

Rapporto P/E:

-2.6912

EPS:

-3.348

Flusso di cassa netto:

$-84.46M

1 W Prestazione:

-13.28%

1M Prestazione:

-17.87%

6M Prestazione:

+10.96%

1 anno Prestazione:

+48.93%

Intervallo 1D:

$8.87

$9.465

Intervallo di 1 settimana:

$8.82

$10.77

Portata 52W:

$5.45

$12.49

Kura Oncology Inc Stock (KURA) Company Profile

Nome

Kura Oncology Inc

Settore

Healthcare (1079)

Industria

Biotechnology (598)

Telefono

(858) 500-8800

Indirizzo

4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA

Dipendente

260

Cinguettio

@kuraoncology

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

KURA's Discussions on Twitter

Compare KURA vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KURA Kura Oncology Inc	9.01	901.06M	71.64M	-294.57M	-84.46M	-3.348
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-14	Iniziato	Lake Street	Buy
2025-09-04	Iniziato	Guggenheim	Neutral
2025-02-06	Downgrade	BTIG Research	Buy → Neutral
2024-10-24	Iniziato	UBS	Buy
2024-10-14	Downgrade	Stifel	Buy → Hold
2023-12-22	Iniziato	Mizuho	Buy
2023-08-11	Iniziato	BofA Securities	Buy
2023-07-27	Iniziato	Scotiabank	Sector Perform
2023-05-17	Iniziato	BTIG Research	Buy
2023-01-31	Iniziato	Stifel	Buy
2022-07-12	Iniziato	Cantor Fitzgerald	Overweight
2022-02-15	Iniziato	Jefferies	Buy
2021-05-05	Ripresa	Credit Suisse	Outperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2020-12-07	Reiterato	H.C. Wainwright	Buy
2020-12-03	Iniziato	Stifel	Buy
2020-11-05	Downgrade	Piper Sandler	Overweight → Neutral
2020-07-07	Iniziato	Credit Suisse	Outperform
2020-05-05	Iniziato	Barclays	Overweight
2019-07-18	Iniziato	Deutsche Bank	Buy
2018-11-09	Iniziato	Piper Jaffray	Overweight
2018-08-01	Iniziato	H.C. Wainwright	Buy
2016-10-13	Ripresa	Leerink Partners	Outperform
2016-01-22	Iniziato	JMP Securities	Mkt Outperform
2015-12-30	Iniziato	Oppenheimer	Outperform
2015-12-16	Iniziato	Citigroup	Buy

Mostra tutto

Kura Oncology Inc Borsa (KURA) Ultime notizie

Jul 28, 2026

Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma - Bitget

Jul 27, 2026

H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jul 27, 2026

Kura Oncology Reports 50% Response Rate in RCC Combination Study - Yahoo Finance

Jul 27, 2026

Kura Oncology Market Sentiment - Benzinga España

Jul 27, 2026

Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial - Bitget

Jul 27, 2026

KURA Shows Promising Results in Phase 1a Kidney Cancer Trial - GuruFocus

Jul 27, 2026

Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma - Quiver Quantitative

Jul 27, 2026

Kura's Drug Combo Shows 13-Month Median Without Progression - Stock Titan

Jul 27, 2026

Jul 25, 2026